Evidence map›Paper›PMID 30636537›Full record

ArticleVeterinary pathology2019

A Transplantable Syngeneic Allograft Mouse Model for Nongestational Choriocarcinoma of the Ovary.

Ludmila Szabova, Baktiar Karim, Melanie Gordon, Lucy Lu, Nathan Pate, Zoe Weaver Ohler

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Veterinary pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Ludmila Szabova1 Center for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research at the National Cancer Institute-Frederick, Frederick, MD, USA.ORCID 0000-0002-5194-0604
Baktiar Karim2 Pathology Histotechnology Laboratory, Laboratory Animal Sciences Program, Frederick National Laboratory for Cancer Research at the National Cancer Institute-Frederick, Frederick, MD, USA.
Melanie Gordon1 Center for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research at the National Cancer Institute-Frederick, Frederick, MD, USA.
Lucy Lu3 Center for Advanced Preclinical Research, National Cancer Institute-Frederick, Frederick, MD, USA.
Nathan Pate1 Center for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research at the National Cancer Institute-Frederick, Frederick, MD, USA.
Zoe Weaver Ohler1 Center for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research at the National Cancer Institute-Frederick, Frederick, MD, USA.
Frederick National Laboratory for Cancer Research · US

Funding

Development of Novel Preclinical Animal Models - CAPR InfrastructureZIGBC011735 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI SHARAN, SHYAM · 2016 to 2025
$4.3M
CCR NIH HHS HHSN261200800001CIntramural NIH HHS ZIG BC011735NCI NIH HHS HHSN261200800001E
6 · The paper itself

Abstract

Nongestational choriocarcinoma is a rare malignancy in humans with poor prognosis. Naturally occurring choriocarcinoma is also rare in laboratory mice, and no genetic mouse model accurately recapitulates the features of this cancer. Here we report development of a genetically engineered mouse (GEM) model with alterations in Brca2, Trp53, and RB that develops ovarian tumors. Most of the ovarian tumors displayed histological characteristics of nongestational choriocarcinoma of the ovary (NGCO) (47%) with abundant syncytiotrophoblasts and cytotrophoblasts, positive immunolabeling for human chorionic gonadotropin, and positive periodic acid-Schiff reaction. The rest of the ovarian tumors were serous epithelial ovarian carcinoma (SEOC) (26%) or mixed tumors consisting of NGCO and SEOC (26%). We further established syngeneic orthotopic mouse models for NGCO by in vivo passaging of GEM tumors. These metastatic models provide a platform for evaluating new treatment strategies in preclinical studies aimed at improving outcomes in choriocarcinoma patients.

Indexed as

AllograftsAnimalsChoriocarcinoma, Non-gestationalDisease Models, AnimalFemaleMiceMice, TransgenicNeoplasm TransplantationOvarian NeoplasmsOvaryneoplasianongestational choriocarcinomaRbserous epithelial ovarian carcinomasyngeneic model

Identifiers

PMID30636537
PMCPMC8459200
OpenAlexW2910489741

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.